[go: up one dir, main page]

WO2005052003A3 - Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis - Google Patents

Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis Download PDF

Info

Publication number
WO2005052003A3
WO2005052003A3 PCT/US2004/038660 US2004038660W WO2005052003A3 WO 2005052003 A3 WO2005052003 A3 WO 2005052003A3 US 2004038660 W US2004038660 W US 2004038660W WO 2005052003 A3 WO2005052003 A3 WO 2005052003A3
Authority
WO
WIPO (PCT)
Prior art keywords
laminin
metastasis
chain
antibodies
tumor growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/038660
Other languages
French (fr)
Other versions
WO2005052003A2 (en
Inventor
Karl Tryggvason
Sirpa Salo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biostratum Inc
Original Assignee
Biostratum Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostratum Inc filed Critical Biostratum Inc
Publication of WO2005052003A2 publication Critical patent/WO2005052003A2/en
Publication of WO2005052003A3 publication Critical patent/WO2005052003A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides antibodies against the laminin 5 Ϝ2 chain, compositions thereof and methods for inhibiting tumor growth and/or metastasis using such antibodies and compositions.
PCT/US2004/038660 2003-11-20 2004-11-18 Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis Ceased WO2005052003A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52389503P 2003-11-20 2003-11-20
US60/523,895 2003-11-20

Publications (2)

Publication Number Publication Date
WO2005052003A2 WO2005052003A2 (en) 2005-06-09
WO2005052003A3 true WO2005052003A3 (en) 2005-09-15

Family

ID=34632842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/038660 Ceased WO2005052003A2 (en) 2003-11-20 2004-11-18 Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis

Country Status (1)

Country Link
WO (1) WO2005052003A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545845B2 (en) 2008-06-18 2013-10-01 Karl Tryggvason Antibodies against domains of laminin-332

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198884A1 (en) 2008-12-18 2010-06-23 Centre National de la Recherche Scientifique (CNRS) Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039401A2 (en) * 2002-10-29 2004-05-13 Sirpa Salo Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis
US20040120959A1 (en) * 2001-01-08 2004-06-24 Karl Tryggvason Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120959A1 (en) * 2001-01-08 2004-06-24 Karl Tryggvason Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis
WO2004039401A2 (en) * 2002-10-29 2004-05-13 Sirpa Salo Use of antibodies to the gamma 2 chain of lallminin 5 to inhibit tumor growth and metastasis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOSHIKAWA NAOHIKO ET AL: "Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 21, 1 November 1999 (1999-11-01), pages 5596 - 5601, XP002214130, ISSN: 0008-5472 *
SIRPA SALO ET AL.: "Laminin-5 promotes adhesion and migration of epithelial cells: identification of a migration-related element in the gamma2 chain gene (LAMC2) with activity in transgenic mice", MATRIX BIOLOGY, vol. 18, 1999, pages 197 - 210, XP002317649 *
STOLTZFUS PATRICIA ET AL: "Laminin-5 gamma2 chain expression facilitates detection of invasive squamous cell carcinoma of the uterine cervix", INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, vol. 23, no. 3, July 2004 (2004-07-01), pages 215 - 222, XP002333471, ISSN: 0277-1691 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545845B2 (en) 2008-06-18 2013-10-01 Karl Tryggvason Antibodies against domains of laminin-332

Also Published As

Publication number Publication date
WO2005052003A2 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2004069152A3 (en) Δ4,5 glycuronidase and uses thereof
HRP20181459T1 (en) Humanized anti-beta7 antagonists and uses thererfor
ZA200701656B (en) Humanized anti-cment antagonists
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
EP1628530B8 (en) Methods and compositions for the prevention and treatment of sepsis
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
MX2007005221A (en) Ascomycin crystalline forms and preparation thereof.
WO2005009928A3 (en) Preparation and use of alkylating agents
WO2004087073A3 (en) Treatment of demyelinating conditions
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
AU2003297568A8 (en) Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith
WO2005115431A3 (en) Methods for inhibiting proteasome and heat shock protein 90
MXPA05005484A (en) Method for enhancing the physico-chemical properties of bitumen compositions and novel bitumen compositions with enhanced properties and their uses.
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2004058705A3 (en) Inhibitors of the binding of chemokines i-tac or sdf-1 to the ccxckr2 receptor
WO2006133006A3 (en) 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
WO2005052003A3 (en) Use of antibodies to the gamma 2 chain of laminin 5 to inhibit tumor growth and metastasis
TW200621744A (en) Mercaptoamides as histone deacetylase inhibitors
WO2004103289A3 (en) Driverse thyroid hormone receptor antagonists and uses thereof
WO2004043400A3 (en) Peptide deformylase activated prodrugs
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
WO2004050834A3 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
ZA200408272B (en) Compositions for improving the flavor of alcoholicbeverage made from grape.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase